Nurix Therapeutics(NRIX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

NRIX Nurix Therapeutics

Closed 02-04 16:00:00 EST

16.55

-0.24

-1.43%

盘后16.55

+0.000.00%

17:53 EST

High16.93	Low16.04	Vol950.56K
Open16.93	D1 Closing16.79	Amplitude5.31%
Mkt Cap1.70B	Tradable Cap1.43B	Total Shares102.84M
T/O15.62M	T/O Rate1.10%	Tradable Shares86.36M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"NRIX","market":"US","secType":"STK","nameCN":"Nurix Therapeutics","latestPrice":16.55,"timestamp":1770238800000,"preClose":16.79,"halted":0,"volume":950561,"hourTrading":{"tag":"盘后","latestPrice":16.55,"preClose":16.55,"latestTime":"17:53 EST","volume":152098,"amount":2517221.9,"timestamp":1770245626932,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.014294222751637787,"floatShares":86361800,"shares":102843000,"eps":-3.051418,"marketStatus":"Closed","change":-0.24,"latestTime":"02-04 16:00:00 EST","open":16.93,"high":16.93,"low":16.0384,"amount":15621615.480661,"amplitude":0.053103,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.051418,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1770282000000},"marketStatusCode":5,"adr":0,"listingDate":1595563200000,"exchange":"NASDAQ","adjPreClose":16.79,"preHourTrading":{"tag":"盘前","latestPrice":17.01,"preClose":16.79,"latestTime":"09:29 EST","volume":670,"amount":11188.72061,"timestamp":1770215362040,"change":0.22,"changeRate":0.013103,"amplitude":0.023228},"postHourTrading":{"tag":"盘后","latestPrice":16.55,"preClose":16.55,"latestTime":"17:53 EST","volume":152098,"amount":2517221.9,"timestamp":1770245626932,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.739276,"impliedVol":0.7353,"impliedVolPercentile":0.3187},"requestUrl":"/m/hq/s/NRIX","defaultTab":"news","newsList":[{"id":"1105395362","title":"Stock Track | Nurix Therapeutics Plummets 5% Intraday on Q4 Losses and Foreign Exchange Risk Concerns","url":"https://stock-news.laohu8.com/highlight/detail?id=1105395362","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1105395362?lang=en_us&edition=fundamental","pubTime":"2026-01-30 23:24","pubTimestamp":1769786683,"startTime":"0","endTime":"0","summary":"Nurix Therapeutics' stock plummeted 5% during intraday trading on Friday, reflecting heightened investor concerns following recent financial disclosures and risk assessments.The decline comes after...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["NRIX"],"gpt_icon":0},{"id":"2607048437","title":"Nurix Therapeutics (NRIX) Q4 Loss Highlights Ongoing Profitability Concerns Despite Revenue Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=2607048437","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607048437?lang=en_us&edition=fundamental","pubTime":"2026-01-30 16:29","pubTimestamp":1769761757,"startTime":"0","endTime":"0","summary":"Nurix Therapeutics (NRIX) closed out FY 2025 with Q4 revenue of US$13.6 million and a basic EPS loss of US$0.82, while the trailing twelve months show revenue of US$84.0 million and a basic EPS loss of US$3.05. Over recent periods, the company has seen quarterly revenue range from US$7.9 million to US$44.1 million and basic EPS losses move between US$0.52 and US$1.03 per quarter. This sets the backdrop for what remains an early stage, loss making biotech story. For investors, the key question...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nrix/nurix-therapeutics/news/nurix-therapeutics-nrix-q4-loss-highlights-ongoing-profitabi","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nrix/nurix-therapeutics/news/nurix-therapeutics-nrix-q4-loss-highlights-ongoing-profitabi","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["NRIX","PRGS"],"gpt_icon":0},{"id":"2607093147","title":"Nurix Therapeutics Exposed to Significant Foreign Exchange Risk Amid Unhedged Currency Exposure","url":"https://stock-news.laohu8.com/highlight/detail?id=2607093147","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607093147?lang=en_us&edition=fundamental","pubTime":"2026-01-30 14:00","pubTimestamp":1769752855,"startTime":"0","endTime":"0","summary":"Nurix Therapeutics, Inc. (NRIX) has disclosed a new risk, in the Capital Markets category. Nurix Therapeutics, Inc. faces meaningful foreign exchan...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/nurix-therapeutics-exposed-to-significant-foreign-exchange-risk-amid-unhedged-currency-exposure?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/nurix-therapeutics-exposed-to-significant-foreign-exchange-risk-amid-unhedged-currency-exposure?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NRIX","BK4139"],"gpt_icon":0},{"id":"2607034171","title":"Nurix Therapeutics Is Maintained at Overweight by Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2607034171","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607034171?lang=en_us&edition=fundamental","pubTime":"2026-01-30 00:42","pubTimestamp":1769704920,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NRIX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 29, 2026 11:42 ET (16:42 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRIX"],"gpt_icon":0},{"id":"1111756655","title":"Stock Track | Nurix Therapeutics Soars 5.90% in Intraday Trading on Positive Analyst Ratings","url":"https://stock-news.laohu8.com/highlight/detail?id=1111756655","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1111756655?lang=en_us&edition=fundamental","pubTime":"2026-01-29 22:32","pubTimestamp":1769697176,"startTime":"0","endTime":"0","summary":"Nurix Therapeutics' stock surged 5.90% during intraday trading on Thursday, reflecting strong investor confidence in the biotechnology company.The price increase follows a series of positive analyst...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["NRIX"],"gpt_icon":0},{"id":"2607084233","title":"Analysts Offer Insights on Healthcare Companies: Palvella Therapeutics (PVLA), Nurix Therapeutics (NRIX) and Jazz Pharmaceuticals (JAZZ)","url":"https://stock-news.laohu8.com/highlight/detail?id=2607084233","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607084233?lang=en_us&edition=fundamental","pubTime":"2026-01-29 20:20","pubTimestamp":1769689217,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Palvella Therapeutics (PVLA – Research Report), Nuri...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-palvella-therapeutics-pvla-nurix-therapeutics-nrix-and-jazz-pharmaceuticals-jazz-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-palvella-therapeutics-pvla-nurix-therapeutics-nrix-and-jazz-pharmaceuticals-jazz-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4532","XBI","PVLA","BK4585","IE00BN0W2V16.EUR","LU0154245673.USD","BK4581","LU0823416689.USD","XLV","IE00BN0W2T93.GBP","IE00BN0W2W23.USD","LABU","LU0320765992.SGD","BK4533","BK4007","LU0029874061.USD","BK4139","LU0109394709.USD","LU0128526141.USD","HCSG","BK4137","JAZZ","NRIX","LU0154245756.USD","LU0889565916.HKD","BK4588"],"gpt_icon":0},{"id":"2607690084","title":"RBC Raises Price Target on Nurix Therapeutics to $30 From $28, Keeps Outperform, Speculative Risk","url":"https://stock-news.laohu8.com/highlight/detail?id=2607690084","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607690084?lang=en_us&edition=fundamental","pubTime":"2026-01-29 20:15","pubTimestamp":1769688908,"startTime":"0","endTime":"0","summary":"Nurix Therapeutics (NRIX) has an average rating of buy and mean price target of $30, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major ban","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NRIX"],"gpt_icon":0},{"id":"2607086031","title":"Nurix Therapeutics Price Target Maintained With a $26.00/Share by Needham","url":"https://stock-news.laohu8.com/highlight/detail?id=2607086031","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607086031?lang=en_us&edition=fundamental","pubTime":"2026-01-29 19:35","pubTimestamp":1769686500,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NRIX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 29, 2026 06:35 ET (11:35 GMT)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRIX"],"gpt_icon":0},{"id":"2607086558","title":"Nurix Therapeutics price target raised to $32 from $31 at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2607086558","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607086558?lang=en_us&edition=fundamental","pubTime":"2026-01-29 19:10","pubTimestamp":1769685051,"startTime":"0","endTime":"0","summary":"H.C. Wainwright raised the firm’s price target on Nurix Therapeutics (NRIX) to $32 from $31 and keeps a Buy rating on the shares. The firm updated ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nurix-therapeutics-price-target-raised-to-32-from-31-at-h-c-wainwright-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nurix-therapeutics-price-target-raised-to-32-from-31-at-h-c-wainwright-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NRIX"],"gpt_icon":0},{"id":"2607725193","title":"Nurix Therapeutics reports Q4 EPS (82c), consensus (92c)","url":"https://stock-news.laohu8.com/highlight/detail?id=2607725193","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607725193?lang=en_us&edition=fundamental","pubTime":"2026-01-29 05:51","pubTimestamp":1769637063,"startTime":"0","endTime":"0","summary":"Reports Q4 revenue $13.6M, consensus $13.41M. “The fourth quarter marked a pivotal inflection point for Nurix as we initiated the DAYBreak registra...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nurix-therapeutics-reports-q4-eps-82c-consensus-92c-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nurix-therapeutics-reports-q4-eps-82c-consensus-92c-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NRIX"],"gpt_icon":0},{"id":"2607474008","title":"Australia's Nurix Therapeutics Q4 net loss widens","url":"https://stock-news.laohu8.com/highlight/detail?id=2607474008","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607474008?lang=en_us&edition=fundamental","pubTime":"2026-01-29 05:13","pubTimestamp":1769634786,"startTime":"0","endTime":"0","summary":"Australia's Nurix Therapeutics Q4 net loss widensOverviewBiopharmaceutical firm's fiscal Q4 revenue rose slightly yr/yrCompany reported a net loss for Q4, widening from the previous yearInitiated DAYB","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260128:nL1N3YT1CC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NRIX"],"gpt_icon":0},{"id":"2607396740","title":"Nurix Therapeutics Appoints Roger Dansey to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2607396740","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607396740?lang=en_us&edition=fundamental","pubTime":"2026-01-29 05:04","pubTimestamp":1769634275,"startTime":"0","endTime":"0","summary":"Nurix Therapeutics Inc. announced the appointment of Roger Dansey, M.D., to its Board of Directors. Dr. Dansey brings expertise in oncology research, clinical development, and commercialization as the company advances its late-stage programs.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nurix Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 28, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260128:nNDL3020ZL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NRIX"],"gpt_icon":0},{"id":"2607406867","title":"Nurix Therapeutics Q4 EPS $(0.82) Beats $(0.92) Estimate, Sales $13.577M Miss $14.309M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2607406867","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607406867?lang=en_us&edition=fundamental","pubTime":"2026-01-29 05:04","pubTimestamp":1769634270,"startTime":"0","endTime":"0","summary":"Nurix Therapeutics Q4 EPS $(0.82) Beats $(0.92) Estimate, Sales $13.577M Miss $14.309M Estimate","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/01/50208338/nurix-therapeutics-q4-eps-0-82-beats-0-92-estimate-sales-13-577m-miss-14-309m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Nurix Therapeutics Q4 EPS $(0.82) Beats $(0.92) Estimate, Sales $13.577M Miss $14.309M Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRIX"],"gpt_icon":0},{"id":"2607470627","title":"Nurix Therapeutics Q4 Net Income USD -78.221 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2607470627","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607470627?lang=en_us&edition=fundamental","pubTime":"2026-01-29 05:01","pubTimestamp":1769634061,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260128:nPLX4C5D3C:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NRIX","BK4139"],"gpt_icon":0},{"id":"2607740100","title":"Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides a Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2607740100","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607740100?lang=en_us&edition=fundamental","pubTime":"2026-01-29 05:01","pubTimestamp":1769634060,"startTime":"0","endTime":"0","summary":"First patients dosed in DAYBreak registrational program for bexobrutideg in relapsed/refractory CLL Presented Phase 1 results at ASH 2025 that support bexobrutideg’s potential best-in-class profile in","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/28/3228040/0/en/Nurix-Therapeutics-Reports-Fourth-Quarter-and-Fiscal-Year-2025-Financial-Results-and-Provides-a-Corporate-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0069063385.USD","LU2308191902.HKD","BK4139","LU1989772923.USD","LU2298064838.USD","LU2362541513.USD","LU1430594728.SGD","LU0158827781.USD","BK4566","LU2023250504.SGD","BK4211","PFS","LU2362540622.SGD","LU2041044095.USD","BK4585","LU0057025933.USD","LU0158827948.USD","LU2023250843.SGD","LU0347712357.USD","LU2229751404.USD","NRIX","LU2089284900.SGD","LU2413666426.HKD","LU2089283258.USD","LU2028103732.USD","BK4533","LU2362541273.HKD","LU2463526074.USD","LU2106854487.HKD","LU0289739343.SGD","LU1939255532.USD","LU0289961442.SGD","BK4534","LU0511384066.AUD","LU1917777945.USD","ORR","WM","ASH","LU0689626769.HKD","LU1623119135.USD","LU0472753341.HKD","BK4195","LU1923621640.USD","LU2092937221.SGD","LU1721428933.USD","LU0124676726.USD","LU2240825500.USD","LU1712237335.SGD","BK4120","LU1585245621.USD"],"gpt_icon":0},{"id":"2605239601","title":"Nurix Therapeutics Chief Legal Officer Christine Ring Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2605239601","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605239601?lang=en_us&edition=fundamental","pubTime":"2026-01-21 08:58","pubTimestamp":1768957104,"startTime":"0","endTime":"0","summary":"Christine Ring, Chief Legal Officer of Nurix Therapeutics Inc., has reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nurix Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 20, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260121:nNDL5lQmR0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Nurix Therapeutics Chief Legal Officer Christine Ring Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NRIX","BK4139"],"gpt_icon":0},{"id":"2604119145","title":"RBC Trims Price Target on Nurix Therapeutics to $28 From $29, Keeps Outperform, Speculative Risk","url":"https://stock-news.laohu8.com/highlight/detail?id=2604119145","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604119145?lang=en_us&edition=fundamental","pubTime":"2026-01-20 22:12","pubTimestamp":1768918357,"startTime":"0","endTime":"0","summary":"Nurix Therapeutics (NRIX) has an average rating of buy and mean price target of $29.59, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NRIX"],"gpt_icon":0},{"id":"2603967369","title":"Analysts Are Bullish on These Healthcare Stocks: Palvella Therapeutics (PVLA), Nurix Therapeutics (NRIX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2603967369","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603967369?lang=en_us&edition=fundamental","pubTime":"2026-01-16 21:20","pubTimestamp":1768569611,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Palvella Therapeutics (PVLA – Research Report), Nuri...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-palvella-therapeutics-pvla-nurix-therapeutics-nrix-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-palvella-therapeutics-pvla-nurix-therapeutics-nrix-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0128526141.USD","LABU","BK4581","BK4585","BK4139","BK4588","BK4112","BK4137","LU0029874061.USD","PVLA","XBI","NRIX"],"gpt_icon":0},{"id":"2603666033","title":"Mizuho Securities Remains a Buy on Nurix Therapeutics (NRIX)","url":"https://stock-news.laohu8.com/highlight/detail?id=2603666033","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603666033?lang=en_us&edition=fundamental","pubTime":"2026-01-14 15:15","pubTimestamp":1768374944,"startTime":"0","endTime":"0","summary":"Mizuho Securities analyst Joseph Catanzaro reiterated a Buy rating on Nurix Therapeutics yesterday. The company’s shares closed yesterday at $18.93...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/mizuho-securities-remains-a-buy-on-nurix-therapeutics-nrix-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/mizuho-securities-remains-a-buy-on-nurix-therapeutics-nrix-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4207","MFG","BK4139","NRIX"],"gpt_icon":0},{"id":"2603863688","title":"Do Analyst Upgrades Clarify Nurix Therapeutics’ (NRIX) True Potential Or Complicate Its Valuation Story?","url":"https://stock-news.laohu8.com/highlight/detail?id=2603863688","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603863688?lang=en_us&edition=fundamental","pubTime":"2026-01-13 14:13","pubTimestamp":1768284809,"startTime":"0","endTime":"0","summary":"Nurix Therapeutics recently presented at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, with CEO Arthur T. Sands outlining the company’s latest developments to investors and industry participants.\nA subsequent wave of analyst upgrades and an overall Outperform consensus have put fresh attention on how the market evaluates Nurix’s prospects.\nNext, we will examine how this cluster of analyst upgrades shapes Nurix Therapeutics’ investment narrative in light of its recent...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nrix/nurix-therapeutics/news/do-analyst-upgrades-clarify-nurix-therapeutics-nrix-true-pot","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-nrix/nurix-therapeutics/news/do-analyst-upgrades-clarify-nurix-therapeutics-nrix-true-pot","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["NRIX"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.nurixtx.com","stockEarnings":[{"period":"1week","weight":-0.135},{"period":"1month","weight":-0.0703},{"period":"3month","weight":0.3481},{"period":"6month","weight":0.6673},{"period":"1year","weight":-0.114},{"period":"ytd","weight":-0.1149}],"compareEarnings":[{"period":"1week","weight":-0.0086},{"period":"1month","weight":0.0093},{"period":"3month","weight":0.0176},{"period":"6month","weight":0.0906},{"period":"1year","weight":0.1535},{"period":"ytd","weight":0.0112}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing DeTIL-0255, a drug-enhanced investigational cell therapy product that uses NX-0255 ex vivo to enhance tumor infiltrating lymphocytes propagation and phenotypic characteristics. The company has a strategic collaboration agreement with Gilead Sciences, Inc. to discover, develop, and commercialize a pipeline of protein degradation drugs for patients with cancer and other challenging diseases; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. The company was incorporated in 2009 and is headquartered in San Francisco, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.5,"avgChangeRate":-0.074756},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.003659},{"month":3,"riseRate":0.2,"avgChangeRate":-0.071924},{"month":4,"riseRate":0.4,"avgChangeRate":-0.043438},{"month":5,"riseRate":0.4,"avgChangeRate":-0.000824},{"month":6,"riseRate":0.6,"avgChangeRate":0.118065},{"month":7,"riseRate":0.6,"avgChangeRate":0.085462},{"month":8,"riseRate":0.5,"avgChangeRate":0.016029},{"month":9,"riseRate":0.166667,"avgChangeRate":0.009437},{"month":10,"riseRate":0.5,"avgChangeRate":0.003905},{"month":11,"riseRate":0.5,"avgChangeRate":0.149774},{"month":12,"riseRate":0.5,"avgChangeRate":0.041068}],"exchange":"NASDAQ","name":"Nurix Therapeutics","nameEN":"Nurix Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Nurix Therapeutics(NRIX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Nurix Therapeutics(NRIX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Nurix Therapeutics,NRIX,Nurix Therapeutics股票,Nurix Therapeutics股票老虎,Nurix Therapeutics股票老虎国际,Nurix Therapeutics行情,Nurix Therapeutics股票行情,Nurix Therapeutics股价,Nurix Therapeutics股市,Nurix Therapeutics股票价格,Nurix Therapeutics股票交易,Nurix Therapeutics股票购买,Nurix Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Nurix Therapeutics(NRIX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Nurix Therapeutics(NRIX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}